Pajjiż: Irlanda
Lingwa: Ingliż
Sors: HPRA (Health Products Regulatory Authority)
Diclofenac epolamine
IBSA Farmaceutici Italia S.r.l
M02AA; M02AA15
Diclofenac epolamine
140 milligram(s)
Medicated plaster
Product subject to prescription which may be renewed (B)
Antiinflammatory preparations, non-steroids for topical use; diclofenac
Marketed
2003-11-04
PATIENT LEAFLET: INFORMATION FOR THE USER FLECTOR TISSUGEL® 140 MG MEDICATED PLASTER DICLOFENAC SODIUM (AS DICLOFENAC EPOLAMINE) READ ALL OF THIS LEAFLET CAREFULLY BEFORE START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Flector Tissugel is and what it is used for 2. What you need to know before you use Flector Tissugel 3. How to use Flector Tissugel 4. Possible side effects 5. How to store Flector Tissugel 6. Contents of the pack and other information. 1. WHAT FLECTOR TISSUGEL IS AND WHAT IT IS USED FOR Flector Tissugel belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs reduce pain and inflammation. Flector Tissugel is used to relieve the pain and inflammation of tennis elbow, golfer’s elbow and a sprained ankle. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE FLECTOR TISSUGEL DO NOT USE FLECTOR TISSUGEL: if you are allergic to diclofenac, acetylsalicylic acid (aspirin) or any other NSAID if you are allergic to any of the other ingredients of Flector Tissugel (listed in section 6) if you have asthma, breathing problems, skin rash or a runny nose after taking acetylsalicylic acid (aspirin) or other NSAIDs if you are entering or are already beyond your 6 th month of pregnancy if you currently have a stomach ulcer (peptic ulcer) if you have any damaged skin including weeping or infected areas, eczema, burns or wounds if you are a children or adolescent aged less than 16 years. If any of the above applies to you talk to your doctor or pharmacist. WARNINGS AND PRECAUTIONS TALK Aqra d-dokument sħiħ
Health Products Regulatory Authority 23 April 2021 CRN00C2N7 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Flector Tissugel 140 mg medicated plaster 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 140 cm 2 (10 cm x 14 cm) of medicated plaster contains a total of 180 mg of diclofenac epolamine corresponding to 140 mg of diclofenac sodium (1% w/w). Excipients: methyl parahydroxybenzoate (E218): 14 mg propyl parahydroxybenzoate (E216): 7 mg propylene glycol: 420 mg Dalin PH perfume containing amyl cinnamal, amylcinnamyl alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnamal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farnesol, geraniol, hexyl cinnamaldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptine carbonate Referred to amount per plaster. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Medicated plaster. White to pale yellow paste spread as a uniform layer onto unwoven support. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Local symptomatic treatment of pain in epicondylitis and ankle sprain. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Cutaneous use only POSOLOGY Adults and adolescents 16 years and older - Symptomatic treatment of ankle sprains : 1 application a day - Symptomatic treatment of epicondylitis : 1 application morning and evening. DURATION OF ADMINISTRATION Flector Tissugel is to be used for as short as possible depending on the indication: - Symptomatic treatment of ankle sprains : 3 days - Symptomatic treatment of epicondylitis : max. 14 days. If there is no improvement, during the recommended duration of treatment or symptoms worsen, a doctor should be consulted. _Elderly_ This medication should be used with caution in elderly patients who are more prone to adverse events. See also Section 4.4. _Children and adolescents below 16 years_ Health Products Regulatory Authority 23 April 2021 CRN00C2N7 Page 2 of 6 There are insufficient data on efficacy and safety available for children and adolescents below Aqra d-dokument sħiħ